Condition (MeSH)
Progeria
ClinicalTrials.gov lists 12 trials for Progeria or a narrower condition beneath it. PRG Science & Technology Co., Ltd. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 12 trials are tagged with Progeria itself; the rest are tagged with a narrower condition beneath it.
When did Progeria trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2015 | 1 |
| 2009 | 2 |
| 2008 | 1 |
| 2007 | 1 |
| 2004 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 12 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Progeria trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 2 |
| Phase 2 | 5 |
| Observational | 3 |
| Expanded access | 1 |
How many Progeria trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Enrolling by invitation | 1 |
| Completed | 7 |
| Approved for marketing | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Progeria trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| PRG Science & Technology Co., Ltd. | 2 |
| Eiger BioPharmaceuticals | 1 |
| National Human Genome Research Institute (NHGRI) | 1 |
Which drugs are being tested for Progeria? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Lonafarnib | 4 |
| Progerinin | 2 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Pravastatin Pill | 1 |
| acid Zoledronic | 1 |
| Lonafarnib, Zoledronic Acid, and Pravastatin | 1 |
| Umbilical Cord Blood Unit | 1 |
| Zoledronic acid, pravastatin | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Progeria trials report? (7)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Stroke | 3 | 1 |
| Vomiting | 2 | 1 |
| Bacterial infection | 1 | 1 |
| Extremity-lower (gait/walking) | 1 | 1 |
| Hypokalemia | 1 | 1 |
Showing 5 of 7 adverse events.
Which publications cover Progeria? (20)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies. | Genetics in medicine : official journal of the American College of Medical Genetics | 2023 | Yes |
| Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation. | Circulation | 2023 | Yes |
| Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. | JAMA | 2018 | Yes |
| Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. | Circulation | 2016 | Yes |
| Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. | Circulation | 2014 | Yes |
Showing 5 of 20 publications.
Prevalence (4)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Hutchinson-Gilford progeria syndrome | Prevalence at birth | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Hutchinson-Gilford progeria syndrome | Prevalence at birth | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Hutchinson-Gilford progeria syndrome | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Hutchinson-Gilford progeria syndrome | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Hutchinson-Gilford progeria syndrome | 740 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Hutchinson-Gilford progeria syndrome | 740 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.